CNS Pharmaceuticals, Inc. (CNSP) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
2100 West Loop South
Houston, TX 77027
United States of America (the)
Phone
800 946 9185
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
November 08, 2019
| Name | Title | Pay | Year Born |
| Rami Levin | Chief Executive Officer, President & Director | 810,863 | 1969 |
| E. Lynne Kelley | Chief Medical Officer | 288,436 | 1963 |
| Lynne Kelley | Chief Medical Officer | 288,436 | N/A |
| Steve O'Loughlin | Chief Financial Officer | 474,640 | 1985 |
| Christopher S. Downs FP&A | Senior Vice President of Finance | 594,000 | 1978 |
| Dylan Wenke | Chief Business Officer | 0 | N/A |
| Eric Faulkner | Chief Technology Officer | 0 | 1973 |
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.